The U.S. Supreme Court overturned a Fifth Circuit restriction and allowed women to keep receiving the abortion drug mifepristone by mail, without an in-person doctor visit, while a high-stakes lawsuit brought by Louisiana continues to wind through the courts. The 7-2 order, issued Thursday, means access to the drug will likely remain unchanged well into next year.

Only Justices Clarence Thomas and Samuel Alito dissented. Their written objections were blunt, framing the case not as a regulatory technicality but as a direct challenge to the post-Dobbs promise that states could set their own abortion laws.

The practical effect is clear: the FDA's 2023 rule allowing telehealth prescriptions and mail delivery of mifepristone stays in place nationwide, even in states like Louisiana that have banned or sharply restricted abortion. For pro-life advocates who believed the Dobbs decision returned real power to the states, the order is a bitter reminder of how far federal regulatory machinery can reach.

What the court did, and what it didn't

The Supreme Court granted emergency requests from mifepristone manufacturers Danco Laboratories and GenBioPro, staying a Fifth Circuit ruling that had temporarily blocked mail delivery of the drug on May 1. That lower-court action had reinstated an in-person screening requirement, the kind of basic safeguard that existed before the Biden administration loosened the rules.

The high court's unsigned order did not resolve the merits. It simply pressed pause on the restrictions while appeals play out. But in abortion litigation, timing is substance. Every month the mail pipeline stays open is another month states cannot enforce their own laws against pills shipped across their borders.

The Washington Examiner reported that the 7-2 vote left open the possibility the justices could take up the Louisiana case on the merits later. For now, though, the status quo favors the drug companies and the Biden-era regulatory framework they depend on.

Medication abortions accounted for nearly two-thirds of all U.S. abortions in 2023, AP News reported, underscoring the enormous stakes of any rule change.

Thomas and Alito lay down a marker

The two dissenters did not mince words. Justice Thomas wrote that it is "a criminal offense to ship mifepristone for use in abortions" and that the two manufacturers are not entitled to relief to spare them from what he called their losses:

"lost profits from their criminal enterprise."

Justice Alito framed the broader conflict in constitutional terms. He wrote that the case goes to the heart of the court's own precedent in Dobbs v. Jackson Women's Health Organization, which was supposed to restore the right of each state to regulate abortion within its borders:

"What is at stake is the perpetration of a scheme to undermine our decision in Dobbs v. Jackson Women's Health Organization, which restored the right of each State to decide how to regulate abortions within its borders."

Alito also took direct aim at the manufacturers, writing that Danco and GenBioPro "are obviously aware of what is going on yet nevertheless supply the drug and reap profits from its felonious use in Louisiana."

Those are extraordinary words from sitting justices, language that frames the companies not as neutral pharmaceutical suppliers but as knowing participants in conduct that violates state criminal law. The fact that five of their colleagues declined to act on that reasoning tells you where the current court stands, at least procedurally.

The sharp dissents from Alito and Thomas drew immediate attention for their forceful tone and their willingness to name what they see as a deliberate end-run around Dobbs.

Louisiana's case and the post-Dobbs gap

Louisiana filed the underlying lawsuit to challenge Biden administration rules that allowed mifepristone to be prescribed via telehealth and shipped through the mail, even into states that have banned abortion. The state's argument is straightforward: if Dobbs meant anything, it meant states could enforce their own restrictions. A federal regulation that lets drug companies mail abortion pills past state lines guts that authority.

The Fifth Circuit agreed, at least temporarily, when it blocked mail delivery on May 1. But the drug manufacturers immediately asked the Supreme Court to intervene, and within two weeks the justices obliged.

The emergency appeal by mifepristone makers moved at a pace that underscored the commercial interests at play. Danco Laboratories and GenBioPro have built a business model around the loosened access rules. Every day those rules are suspended costs them revenue, a fact Thomas pointedly referenced in his dissent.

Pro-abortion groups celebrated the order. Serra Sippel of The Brigid Alliance told the New York Post, "We are relieved that access to mifepristone remains protected for now, but this should never have been on the table in the first place."

On the other side, Gavin Oxley, a spokesperson for Americans United for Life, called the decision "extremely disappointing" but said it was not a defeat, a recognition that the merits fight is still ahead.

Safety data the FDA would rather not discuss

While the legal battle plays out, a growing body of research is raising uncomfortable questions about the drug at the center of it. An analysis released in 2025 by the Ethics and Public Policy Center examined data from more than 865,000 women who were prescribed mifepristone. The findings were grim.

In nearly 11% of cases, women experienced sepsis, infection, hemorrhaging, or other serious adverse events within 45 days of taking the drug. More than one in 20 women, over 5%, ended up undergoing a second abortion after the pills they initially took failed to complete the procedure. That amounts to 45,498 women who needed a repeat abortion, and of those, 24,563 had to undergo a surgical procedure.

A separate analysis commissioned by the Foundation for the Restoration of America found that about 11.2% of women suffered critical health complications after taking mifepristone in 2023, more than one in ten.

Ryan Anderson and Jamie Bryan Hall, co-authors of the EPPC study, did not hedge their conclusions:

"Simply stated, mifepristone, as used in real-world conditions, is not 'safe and effective.'"

They urged the FDA to "reinstate earlier, stronger patient safety protocols and reconsider its approval of mifepristone altogether. Women deserve better than the abortion pill."

Pro-life groups are pushing the FDA to move faster with a review they hope will restore protective measures, including the in-person visit requirement that the Biden administration stripped away. But the agency has shown no urgency. The FDA has long touted mifepristone as "safe and effective," and the bureaucratic incentive to revisit that conclusion is close to zero.

That institutional inertia matters. When a federal agency refuses to update its safety posture, and a federal court keeps the old rules in place while litigation drags on, the result is that women bear the risk. Nearly 11% adverse-event rates and 5%-plus failure rates are not small numbers. They represent tens of thousands of real women who experienced serious medical complications, many of them at home, without a physician present, because the rules said they didn't need one.

The ongoing fight over mail-order abortion pill access is far from settled, but the pattern is familiar: federal rules expand access, courts defer, and the people who live with the consequences are the last to be heard.

What comes next

The Supreme Court's order is temporary. The Louisiana case will continue in the lower courts, and the justices could eventually take up the merits. But the timeline favors the status quo. Access to mifepristone by mail is likely to remain uninterrupted well into next year as appeals play out.

For states that passed abortion restrictions after Dobbs, the message is discouraging. You can write whatever law you want. If the FDA keeps the pipeline open and the courts keep staying your enforcement, the law is ink on paper and nothing more.

The internal divisions on the court are real, but so far the institutional preference for preserving regulatory access has won out over the states' claim to sovereignty. Thomas and Alito see the contradiction clearly. Whether a majority ever will is the question that hangs over every abortion case still to come.

Several open questions remain unanswered. What specific Biden-era rules are being challenged, and how broadly could a ruling on the merits reshape telehealth prescribing? Will the FDA act on the safety data, or will it wait for a court to force its hand? And if the court eventually rules for Louisiana, will the decision come in time to matter, or will years of uninterrupted mail access have already created facts on the ground that no ruling can undo?

Dobbs promised the states a voice. Right now, the mailbox is louder.